Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
TYRA proposed sale of 53,172 common shares via stock option exercise. The filing lists 53,172 shares to be sold on 03/26/2026 through a stock option exercise for cash to the issuer. The filing also shows 14,295 shares sold in the prior three months on 03/25/2026.
Tyra Biosciences, Inc. Chief Financial Officer Alan Fuhrman increased his holdings through the company’s employee stock purchase plan. On March 13, 2026, he acquired 1,376 shares of common stock at $9.129 per share under the 2021 Employee Stock Purchase Plan. After this ESPP acquisition, he directly owns 16,164 common shares, reflecting a routine, compensation-related increase rather than an open-market purchase.
Tyra Biosciences President and CEO Harris Todd increased his direct holdings through a compensation-related share acquisition. On March 13, 2026, he acquired 1,463 shares of Tyra Biosciences common stock at $9.129 per share under the company’s 2021 Employee Stock Purchase Plan.
After this transaction, Todd directly owns 1,358,631 common shares. This was a grant/award-type acquisition under an employee plan, not an open-market purchase, and represents a small addition relative to his existing stake.
TYRA reported Rule 144 sale notices showing an insider sold blocks of common stock. The filing lists three transactions of 8,000 shares each on 12/12/2025, 01/12/2026, and 02/12/2026. The filing also shows 53,372,098 shares outstanding as of 03/12/2026.
Tyra Biosciences, Inc. received an updated Schedule 13D/A showing RA Capital’s group now beneficially owns 12,266,575 shares of common stock, or 21.2% of the company.
The filing states this change results from dilution of their stake after additional Tyra shares were issued, rather than new buying or selling by the RA Capital entities.
The ownership includes shares held by RA Capital Healthcare Fund, a separately managed account, RA Capital Nexus Fund, and stock options and warrants tied to RA Capital, some of which are subject to a 19.99% beneficial ownership blocker that currently prevents further warrant exercises.
Tyra Biosciences, Inc. entered into an agreement to issue and sell 4,000,000 shares of common stock to a large investment management firm in a block transaction. The shares are priced at $31.50 per share, and Tyra Biosciences expects to receive $126.0 million in gross proceeds upon settlement, before fees and other expenses.
The transaction is being carried out under the company’s existing “at-the-market” offering program, which is registered on Form S-3 under the Securities Act of 1933. The terms of this program are described in a sales agreement prospectus dated May 16, 2025, with related documents available on the SEC’s website.
Tyra Biosciences is a clinical-stage biotechnology company developing next‑generation precision small molecules focused on fibroblast growth factor receptor (FGFR) biology, using its in‑house SNÅP structure‑guided drug design platform.
The lead asset is oral dabogratinib (formerly TYRA‑300), an FGFR3‑selective inhibitor in three Phase 2 programs: SURF303 for low‑grade upper tract urothelial carcinoma, SURF302 for intermediate‑risk non‑muscle invasive bladder cancer, and BEACH301 for achondroplasia in children. The company plans potential registrational trials if Phase 2 data are successful and holds orphan drug and rare pediatric disease designations for achondroplasia.
Additional programs include TYRA‑430, an FGFR4/3‑biased inhibitor in a Phase 1 trial for FGF19‑positive hepatocellular carcinoma, and TYRA‑200, an FGFR1/2/3 inhibitor in Phase 1 for FGFR2‑driven intrahepatic cholangiocarcinoma resistant to prior FGFR therapy. Tyra reports a robust patent estate extending into the 2040s and relies on third‑party manufacturers while retaining global development and commercialization rights to all pipeline assets.
As of June 30, 2025, non‑affiliate common stock market value was approximately $297.3 million, and as of February 25, 2026, there were 53,867,115 shares outstanding.
Tyra Biosciences reported fourth-quarter and full-year 2025 results and outlined progress on its FGFR-focused pipeline. The company ended 2025 with $256.0 million in cash, cash equivalents and marketable securities and expects this to fund operations through at least 2027.
Research and development expenses rose to $28.2 million in Q4 and $102.9 million for 2025, driven mainly by oral dabogratinib clinical programs, including BEACH301 and SURF302 plus start-up for SURF303. General and administrative costs increased to $8.3 million in Q4 and $29.8 million for the year due to higher headcount-related spending.
Net loss was $33.8 million in Q4 and $119.9 million for 2025 as the company continues to invest in development. Tyra emphasized its “dabogratinib 3x3” strategy, concentrating on three Phase 2 studies in LG-UTUC, IR NMIBC and achondroplasia, with key data readouts expected in 2026.
Tyra Biosciences ownership disclosure: a group of Farallon funds and affiliated persons report shared dispositive power over certain blocks of Common Stock, including 2,984,818 shares (5.6%) held in the aggregate by multiple Farallon individual reporting persons. The filing lists additional holdings including 2,828,865 shares (5.3%) attributed to Farallon Partners, L.L.C., and 1,272,095 shares (2.4%) held by Farallon Capital Offshore Investors II, L.P.
The statement describes the reporting group structure, identifies the Farallon Funds and individual managing members, and notes that the reporting persons file under Section 13(d)-1(c).